Apart from reactivation of the MAPK/ERK signaling pathway, cancers acquire resistance to MAPK/ERK signaling-based target therapy by recruiting an alternative signaling pathway that induces cell proliferation and growth. This evidence concerns the gene MAPK1 and cancer.